Format

Send to

Choose Destination
Exp Cell Res. 2013 Jul 1;319(11):1644-9. doi: 10.1016/j.yexcr.2013.03.005. Epub 2013 Mar 13.

B cells and their mediators as targets for therapy in solid tumors.

Author information

1
Department of Cell and Developmental Biology, Oregon Health and Science University, 3181 SW Sam Jackson Park Rd, Mail Code L215, Rm 5508, Richard Jones Hall, Portland, OR 97239-3098, USA.
2
Department of Cell and Developmental Biology, Oregon Health and Science University, 3181 SW Sam Jackson Park Rd, Mail Code L215, Rm 5508, Richard Jones Hall, Portland, OR 97239-3098, USA; Knight Cancer Institute, Oregon Health and Science University, 3181 SW Sam Jackson Park Rd, Mail Code L215, Rm 5508, Richard Jones Hall, Portland, OR 97239-3098, USA. Electronic address: coussenl@ohsu.edu.

Abstract

B cells have recently been appreciated as paracrine mediators of solid tumor development. Their ability to influence various hallmarks of cancer development, aside from antigen presentation, can be attributed to the diversity of soluble mediators they express, including cytokines and immunoglobulins, that can act directly and indirectly on the diversity of leukocyte subsets that infiltrate developing tumors, evolving neoplastic cells, as well as select T cell populations in secondary lymphoid organs and within tumor stroma. Herein, we review the literature supporting these interactions and discuss novel approaches to ameliorate protumoral B cell effects for anti-cancer therapy.

KEYWORDS:

B cells; Cancer; Inflammation; Leukocytes; Myeloid cells

PMID:
23499742
PMCID:
PMC3743954
DOI:
10.1016/j.yexcr.2013.03.005
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center